If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Advanced Merger Partners (AMPI.U)
Anzu Special Acquisition I (ANZU.U)
Nightdragon Acquisition (NDACU)
Supernova Partners Acquisition II (SNII.U)
Dhb Capital (DHBCU)
Orion Acquisition Corp. (OHPAU)
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Live Oak Mobility Acquisition (LOKM.U)
Property Solutions Acquisition II (PSAGU)
Atlantic Coastal Acquisition (ACAHU)
Khosla Ventures Acquisition Co. (KVSA)
TCW Special Purpose Acquisition Corp. (TSPQ.U)
Aurora Acquisition Corp. (AURCU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Roblox Corporation (RBLX)
Coupang, Inc. (CPNG)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Bolt Therapeutics, Inc. (BOLT)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Their proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that directly kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. Their lead product candidate BDC-1001 is a HER2 Boltbody ISAC comprised of a HER2-targeting biosimilar for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. They have demonstrated robust single agent anti-tumor activity in multiple preclinical models, including elimination of large tumors (~500 mm3), as well as tumors that are refractory to trastuzumab or ado-trastuzumab emtansine. In their preclinical safety studies, BDC-1001 was well tolerated and no adverse safety signals were observed. They believe these findings are encouraging for the therapeutic potential of BDC-1001. They initiated a Phase 1/2 trial of BDC-1001 in the first quarter of 2020 for the treatment of patients with HER2-expressing solid tumors. They are currently in the dose escalation portion of the trial and expect to move into Phase 2 dose expansions in key solid tumor indications with unmet medical need in 2021.
Randall C. Schatzman William P. Quinn
Employees Founded
63 2015


Address: 900 Chesapeake Drive Redwood City, California 94063

Telephone: (650) 665-9295

Web page:

IPO information

Expected Date 2/5/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $16.00-$18.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 8.83
Shares Revised (MM) 11.5
Expected offer amount (MM) $194.25
Realized offer amount(MM) $230

Financial Data (last reporting year)

Market Cap (MM) $620.12
Revenues (MM) $0.30
Net Income (Loss) (MM) $-39.05


What do you think will happen with the BOLT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Morgan Stanley/ SVB Leerink/ Stifel/ Guggenheim Securities

Sector: Healthcare

Tweets about $BOLT

Tweets volume:

RT volume:


Google Trends Stats